Another Glaxo respiratory drug sees regulatory filings in its future

GlaxoSmithKline ($GSK) is one step closer to further bolstering its respiratory lineup. The British pharma giant says it's nailed the primary endpoint in a Phase III study of its injectable candidate mepolizumab, which will help set the severe eosinophilic asthma treatment up for its first regulatory filings. Last year, GSK nabbed the FDA's blessing for two potential respiratory blockbusters, Anoro and Breo. But sales of the pair won't touch Advair's $8.25 billion-a-year haul, and the off-patent behemoth has recently seen its market share challenged by both branded and generic rivals. More

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.